Skip to main content

Articles

Page 3 of 29

  1. The independent and additive associations of walking pace and grip strength on dementia risk and the potential modifying effects of age, APOE phenotypes, and other dementia risk factors on the walking pace and...

    Authors: Panpan He, Chun Zhou, Ziliang Ye, Mengyi Liu, Yuanyuan Zhang, Qimeng Wu, Yanjun Zhang, Sisi Yang, Gan Xiaoqin and Xianhui Qin
    Citation: Alzheimer's Research & Therapy 2023 15:9
    Content type: Research Published on:

    The Correction to this article has been published in Alzheimer's Research & Therapy 2023 15:73

  2. High continuity of care (COC) is associated with better clinical outcomes among older adults. The impact of amyloid-β PET scan on COC among adults with mild cognitive impairment (MCI) or dementia of uncertain ...

    Authors: Emily C. O’Brien, Cassie B. Ford, Corinna Sorenson, Eric Jutkowitz, Megan Shepherd-Banigan and Courtney Van Houtven
    Citation: Alzheimer's Research & Therapy 2023 15:6
    Content type: Correspondence Published on:

  3. Dementia and psychotropic medications are discussed as risk factors for severe/lethal outcome of the coronavirus disease 2019 (COVID-19). We aimed to explore the associations between the presence of dementia a...

    Authors: Juraj Secnik, Maria Eriksdotter, Hong Xu, Martin Annetorp, Aleksander Rytarowski, Kristina Johnell, Sara Hägg and Dorota Religa
    Citation: Alzheimer's Research & Therapy 2023 15:5
    Content type: Research Published on:

  5. Behavioral variant frontotemporal dementia (bvFTD) is predominantly considered a dysfunction in cortico-cortical transmission, with limited direct investigation of cortical-subcortical transmission. Thus, we a...

    Authors: Li Liu, Min Chu, Binbin Nie, Deming Jiang, Kexin Xie, Yue Cui, Lin Liu, Yu Kong, Zhongyun Chen, Haitian Nan, Pedro Rosa-Neto and Liyong Wu
    Citation: Alzheimer's Research & Therapy 2023 15:3
    Content type: Research Published on:

  6. Accessible and cost-effective diagnostic tools are urgently needed to accurately quantify blood biomarkers to support early diagnosis of Alzheimer’s disease (AD). In this study, we investigated the ability of ...

    Authors: María Pascual-Lucas, José Antonio Allué, Leticia Sarasa, Noelia Fandos, Sergio Castillo, Jose Terencio, Manuel Sarasa, Juan Pablo Tartari, Ángela Sanabria, Lluís Tárraga, Agustín Ruíz, Marta Marquié, Sang Won Seo, Hyemin Jang and Mercè Boada
    Citation: Alzheimer's Research & Therapy 2023 15:2
    Content type: Research Published on:

  7. Patterns of cognitive impairment in former American football players are uncertain because objective neuropsychological data are lacking. This study characterized the neuropsychological test performance of for...

    Authors: Michael L. Alosco, William B. Barr, Sarah J. Banks, Jennifer V. Wethe, Justin B. Miller, Surya Vamsi Pulukuri, Julia Culhane, Yorghos Tripodis, Charles H. Adler, Laura J. Balcer, Charles Bernick, Megan L. Mariani, Robert C. Cantu, David W. Dodick, Michael D. McClean, Rhoda Au…
    Citation: Alzheimer's Research & Therapy 2023 15:1
    Content type: Research Published on:

  8. Non-modifiable risk factors of Alzheimer’s disease (AD) have lifelong effects on cortical integrity that could be mitigated if identified at early stages. However, it remains unknown whether cortical microstru...

    Authors: Marina Fernandez-Alvarez, Mercedes Atienza and Jose L. Cantero
    Citation: Alzheimer's Research & Therapy 2022 14:202
    Content type: Research Published on:

  9. Alpha-synuclein (α-syn) is considered the main pathophysiological protein component of Lewy bodies in synucleinopathies. α-Syn is an intrinsically disordered protein (IDP), and several types of structural conf...

    Authors: Kyu Hwan Shim, Min Ju Kang, Young Chul Youn, Seong Soo A. An and SangYun Kim
    Citation: Alzheimer's Research & Therapy 2022 14:201
    Content type: Review Published on:

  10. Increasing evidence has supported a link between obstructive sleep apnea (OSA) and cognition, and blood-brain barrier (BBB) dysfunction which can be reflected by paroxysmal slow wave events (PSWEs) may be a po...

    Authors: Mengfan Li, Zhuoran Sun, Hairong Sun, Guochen Zhao, Bing Leng, Tengqun Shen, Song Xue, Huimin Hou, Zhenguang Li and Jinbiao Zhang
    Citation: Alzheimer's Research & Therapy 2022 14:200
    Content type: Research Published on:

  11. Alzheimer’s disease (AD) and frontotemporal dementia (FTD) show network dysfunctions linked with cognitive deficits. Within this framework, network abnormalities between AD and FTD show both convergent and div...

    Authors: Lorenzo Pini, Siemon C de Lange, Francesca Benedetta Pizzini, Ilaria Boscolo Galazzo, Rosa Manenti, Maria Cotelli, Samantha Galluzzi, Maria Sofia Cotelli, Maurizio Corbetta, Martijn P van den Heuvel and Michela Pievani
    Citation: Alzheimer's Research & Therapy 2022 14:199
    Content type: Research Published on:

  12. Efavirenz is an anti-HIV drug, and cytochrome P450 46A1 (CYP46A1) is a CNS-specific enzyme that metabolizes cholesterol to 24-hydroxycholesterol (24HC). We have previously shown that allosteric CYP46A1 activat...

    Authors: Alan J. Lerner, Steven E. Arnold, Erin Maxfield, Aaron Koenig, Maria E. Toth, Brooke Fortin, Natalia Mast, Bianca A. Trombetta, John Denker, Andrew A. Pieper, Curtis Tatsuoka, Sangeetha Raghupathy and Irina A. Pikuleva
    Citation: Alzheimer's Research & Therapy 2022 14:198
    Content type: Research Published on:

  13. The identification of biomarkers for early detection of Alzheimer’s disease (AD) is critical to the development of therapies and interventions targeted at symptom management and tracking the pathophysiology of...

    Authors: Michael D. Oliver, Cassandra Morrison, Farooq Kamal, Jillian Graham and Mahsa Dadar
    Citation: Alzheimer's Research & Therapy 2022 14:197
    Content type: Research Published on:

  14. In Alzheimer’s disease (AD), amyloid-β 1–42 (Aβ42) neurotoxicity stems mostly from its soluble oligomeric aggregates. Studies of such aggregates have been hampered by the lack of oligomer-specific research too...

    Authors: Anders Sandberg, Ernesto Berenjeno-Correa, Rosa Crespo Rodriguez, Michael Axenhus, Sophia Schedin Weiss, Kevin Batenburg, Jeroen J. M. Hoozemans, Lars O. Tjernberg and Wiep Scheper
    Citation: Alzheimer's Research & Therapy 2022 14:196
    Content type: Research Published on:

  15. The extracellular buildup of amyloid beta (Aβ) plaques in the brain is a hallmark of Alzheimer’s disease (AD). Detection of Aβ pathology is essential for AD diagnosis and for identifying and recruiting researc...

    Authors: Abby L. Brand, Paige E. Lawler, James G. Bollinger, Yan Li, Suzanne E. Schindler, Melody Li, Samir Lopez, Vitaliy Ovod, Akinori Nakamura, Leslie M. Shaw, Henrik Zetterberg, Oskar Hansson and Randall J. Bateman
    Citation: Alzheimer's Research & Therapy 2022 14:195
    Content type: Review Published on:

  16. Alzheimer’s disease (AD) shares risk factors with cardiovascular disease (CVD) and dysregulated cholesterol metabolism is a mechanism common to both diseases. Cholesterol efflux capacity (CEC) is an ex vivo me...

    Authors: Yi-An Ko, Jeffrey T. Billheimer, Nicholas N. Lyssenko, Alexandra Kueider-Paisley, David A. Wolk, Steven E. Arnold, Yuk Yee Leung, Leslie M. Shaw, John Q. Trojanowski, Rima F. Kaddurah-Daouk, Mitchel A. Kling and Daniel J. Rader
    Citation: Alzheimer's Research & Therapy 2022 14:194
    Content type: Research Published on:

  17. Hypertension has been associated with Alzheimer’s disease (AD) dementia as well as vascular dementia. However, the underlying neuropathological changes that link hypertension to AD remain poorly understood. In...

    Authors: Taewon Kim, Dahyun Yi, Min Soo Byun, Hyejin Ahn, Joon Hyung Jung, Nayeong Kong, Min Jung Kim, Gijung Jung, Jun-Young Lee, Yun-Sang Lee, Yu Kyeong Kim and Dong Young Lee
    Citation: Alzheimer's Research & Therapy 2022 14:193
    Content type: Research Published on:

  18. Cerebrospinal fluid (CSF) tau biomarkers are reliable diagnostic markers for Alzheimer’s disease (AD). However, their strong association with amyloid pathology may limit their reliability as specific markers o...

    Authors: Joel Simrén, Wagner S. Brum, Nicholas J. Ashton, Andrea L. Benedet, Thomas K. Karikari, Hlin Kvartsberg, Emma Sjons, Firoza Z. Lussier, Mira Chamoun, Jenna Stevenson, Robert Hopewell, Vanessa Pallen, Keqiang Ye, Tharick A. Pascoal, Henrik Zetterberg, Pedro Rosa-Neto…
    Citation: Alzheimer's Research & Therapy 2022 14:192
    Content type: Research Published on:

  19. Lecanemab, a humanized IgG1 monoclonal antibody that targets soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid reduction and slowing of clinical decline in early AD....

    Authors: Eric McDade, Jeffrey L. Cummings, Shobha Dhadda, Chad J. Swanson, Larisa Reyderman, Michio Kanekiyo, Akihiko Koyama, Michael Irizarry, Lynn D. Kramer and Randall J. Bateman
    Citation: Alzheimer's Research & Therapy 2022 14:191
    Content type: Research Published on:

  20. Neuropsychiatric symptoms are important treatment targets in the management of dementia and can be present at very early clinical stages of neurodegenerative diseases. Increased cortisol has been reported in A...

    Authors: Sami Ouanes, Miriam Rabl, Christopher Clark, Clemens Kirschbaum and Julius Popp
    Citation: Alzheimer's Research & Therapy 2022 14:190
    Content type: Research Published on:

  21. Blood-based neurofilament light chain (NfL) is a promising biomarker of neurodegeneration across multiple neurodegenerative diseases. However, blood-based NfL is highly associated with renal function in older ...

    Authors: Rongxiang Tang, Matthew S. Panizzon, Jeremy A. Elman, Nathan A. Gillespie, Richard L. Hauger, Robert A. Rissman, Michael J. Lyons, Michael C. Neale, Chandra A. Reynolds, Carol E. Franz and William S. Kremen
    Citation: Alzheimer's Research & Therapy 2022 14:189
    Content type: Research Published on:

  22. Understanding the treatment needs of patients with dementia with Lewy bodies (DLB) is essential to develop treatment strategies. We examined the treatment needs of patients with DLB and their caregivers and th...

    Authors: Mamoru Hashimoto, Yuta Manabe, Takuhiro Yamaguchi, Shunji Toya and Manabu Ikeda
    Citation: Alzheimer's Research & Therapy 2022 14:188
    Content type: Research Published on:

    The Correction to this article has been published in Alzheimer's Research & Therapy 2023 15:4

  23. Granulovacuolar degeneration bodies (GVBs) are intracellular vesicular structures that commonly accompany pathological tau accumulations in neurons of patients with tauopathies. Recently, we developed the firs...

    Authors: Marta Jorge-Oliva, Jasper F. M. Smits, Vera I. Wiersma, Jeroen J. M. Hoozemans and Wiep Scheper
    Citation: Alzheimer's Research & Therapy 2022 14:187
    Content type: Research Published on:

  24. Alzheimer’s disease has become one of the most common neurodegenerative diseases worldwide, which seriously affects the health of the elderly. Early detection and intervention are the most effective prevention...

    Authors: Qin Yang, Xin Li, Xinyun Ding, Feiyang Xu and Zhenhua Ling
    Citation: Alzheimer's Research & Therapy 2022 14:186
    Content type: Review Published on:

  25. To investigate the characteristics and associations of MRI-visible perivascular spaces (PVS) with clinical progression and longitudinal cognitive decline across the Alzheimer’s disease spectrum.

    Authors: Ming-Liang Wang, Qiao-Qiao Zou, Zheng Sun, Xiao-Er Wei, Peng-Yang Li, Xue Wu and Yue-Hua Li
    Citation: Alzheimer's Research & Therapy 2022 14:185
    Content type: Research Published on:

  26. Growing evidence has showed an association between habitual glucosamine use and type 2 diabetes (T2D). However, the effect of habitual glucosamine use on risk of dementia remains poorly understood. Our study a...

    Authors: Chenjie Xu, Yabing Hou, Xuexian Fang, Hongxi Yang and Zhi Cao
    Citation: Alzheimer's Research & Therapy 2022 14:184
    Content type: Research Published on:

  27. Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease worldwide and remains without effective cure. Increasing evidence is supporting the mitochondrial cascade hypothesis, proposing that los...

    Authors: Christina F. de Veij Mestdagh, Frank Koopmans, Jonathan C. Breiter, Jaap A. Timmerman, Pieter C. Vogelaar, Guido Krenning, Huibert D. Mansvelder, August B. Smit, Robert H. Henning and Ronald E. van Kesteren
    Citation: Alzheimer's Research & Therapy 2022 14:183
    Content type: Research Published on:

  28. Lecanemab (BAN2401) is a humanized IgG1 monoclonal antibody that preferentially targets soluble aggregated Aβ species (protofibrils) with activity at insoluble fibrils and slowed clinical decline in an 18-mont...

    Authors: Shobha Dhadda, Michio Kanekiyo, David Li, Chad J. Swanson, Michael Irizarry, Scott Berry, Lynn D. Kramer and Donald A. Berry
    Citation: Alzheimer's Research & Therapy 2022 14:182
    Content type: Research Published on:

  29. Neuronal- and astrocyte-derived exosomes have been identified as an optimal source for screening biomarkers for Alzheimer’s disease (AD). However, few studies focus on the bulk exosome population isolated from...

    Authors: Huimin Cai, Yana Pang, Qi Wang, Wei Qin, Cuibai Wei, Ying Li, Tingting Li, Fangyu Li, Qigeng Wang, Yan Li, Yiping Wei and Longfei Jia
    Citation: Alzheimer's Research & Therapy 2022 14:181
    Content type: Research Published on:

  30. Aggregation of the amyloid-β (Aβ) peptide in the brain is one of the key pathological events in Alzheimer’s disease (AD). Reducing Aβ levels in the brain by enhancing its degradation is one possible strategy t...

    Authors: Fadi Rofo, Nicole G. Metzendorf, Cristina Saubi, Laura Suominen, Ana Godec, Dag Sehlin, Stina Syvänen and Greta Hultqvist
    Citation: Alzheimer's Research & Therapy 2022 14:180
    Content type: Research Published on:

  31. Synaptic degeneration is an early event closely associated with the course of Alzheimer’s disease (AD). The identification of synaptic blood biomarkers is, therefore, of great interest and clinical relevance. ...

    Authors: Pablo Mohaupt, Marie-Laure Pons, Jérôme Vialaret, Constance Delaby, Christophe Hirtz and Sylvain Lehmann
    Citation: Alzheimer's Research & Therapy 2022 14:179
    Content type: Mini Review Published on:

  32. This review describes the research and development process of gantenerumab, a fully human anti-amyloid monoclonal antibody in development to treat early symptomatic and asymptomatic Alzheimer’s disease (AD). A...

    Authors: Randall J. Bateman, Jeffrey Cummings, Scott Schobel, Stephen Salloway, Bruno Vellas, Mercè Boada, Sandra E. Black, Kaj Blennow, Paulo Fontoura, Gregory Klein, Sheila Seleri Assunção, Janice Smith and Rachelle S. Doody
    Citation: Alzheimer's Research & Therapy 2022 14:178
    Content type: Review Published on:

  33. Aggregated amyloid-β (Aβ) is considered a pathogenic initiator of Alzheimer’s disease (AD), in strong association with tau hyperphosphorylation, neuroinflammation, synaptic dysfunction, and cognitive decline. ...

    Authors: Hee Yang Lee, Soljee Yoon, Jeong Hwa Lee, Keunwan Park, Youngeun Jung, Illhwan Cho, Donghee Lee, Jisu Shin, Kyeonghwan Kim, Sunmi Kim, Jimin Kim, Koeun Kim, Seung Hoon Han, Seong Muk Kim, Hye Ju Kim, Hye Yun Kim…
    Citation: Alzheimer's Research & Therapy 2022 14:177
    Content type: Research Published on:

  34. Individuals with Down syndrome (DS) are increasingly eligible for clinical trial intervention, particularly for the treatment or prevention of Alzheimer disease (AD). Yet, little is known about research attitu...

    Authors: Ira T. Lott, Katharine A. Kirby, Eric Doran and Joshua D. Grill
    Citation: Alzheimer's Research & Therapy 2022 14:176
    Content type: Research Published on:

  35. Visinin-like protein 1 (VILIP-1) belongs to the group of emerging biomarkers with the potential to support the early diagnosis of Alzheimer’s disease (AD). However, studies investigating the differential diagn...

    Authors: Steffen Halbgebauer, Petra Steinacker, Daniel Riedel, Patrick Oeckl, Sarah Anderl-Straub, Jolina Lombardi, Christine A. F. von Arnim, Magdalena Nagl, Armin Giese, Albert C. Ludolph and Markus Otto
    Citation: Alzheimer's Research & Therapy 2022 14:175
    Content type: Research Published on:

  36. Robust and accessible biomarkers that can capture the heterogeneity of Alzheimer’s disease and its diverse pathological processes are urgently needed. Here, we undertook an investigation of Alzheimer’s disease...

    Authors: Eric B. Dammer, Lingyan Ping, Duc M. Duong, Erica S. Modeste, Nicholas T. Seyfried, James J. Lah, Allan I. Levey and Erik C. B. Johnson
    Citation: Alzheimer's Research & Therapy 2022 14:174
    Content type: Research Published on:

  37. The enrollment into clinical trials of persons at risk for autosomal dominant Alzheimer’s disease (ADAD) in whom the onset of disease can be accurately predicted facilitates the interpretation of outcomes (e.g...

    Authors: Angélica Zuno-Reyes, Esmeralda Matute, Karin Ernstrom, Mellissa Withers, Yaneth Rodriguez-Agudelo, Rema Raman and John M. Ringman
    Citation: Alzheimer's Research & Therapy 2022 14:173
    Content type: Research Published on:

  38. The recent promise of disease-modifying therapies for Alzheimer’s disease (AD) has reinforced the need for accurate biomarkers for early disease detection, diagnosis and treatment monitoring. Advances in the d...

    Authors: Edward N. Wilson, Christina B. Young, Javier Ramos Benitez, Michelle S. Swarovski, Igor Feinstein, Manu Vandijck, Yann Le Guen, Nandita M. Kasireddy, Marian Shahid, Nicole K. Corso, Qian Wang, Gabriel Kennedy, Alexandra N. Trelle, Betty Lind, Divya Channappa, Malia Belnap…
    Citation: Alzheimer's Research & Therapy 2022 14:172
    Content type: Research Published on:

  39. The effectiveness, safety, and cost-effectiveness of the use of Souvenaid for Alzheimer’s disease (AD) have been previously evidenced. To complete the economic analysis, there is a need to assess whether socie...

    Authors: Javier Mar, Oliver Ibarrondo, Igor Larrañaga, Lorea Mar-Barrutia and Myriam Soto-Gordoa
    Citation: Alzheimer's Research & Therapy 2022 14:171
    Content type: Research Published on:

  40. Early diagnosis of mild cognitive impairment (MCI) is essential for timely treatment planning. With recent advances in the wearable technology, interest has increasingly shifted toward computer-aided self-diag...

    Authors: Kyeonggu Lee, Kang-Min Choi, Seonghun Park, Seung-Hwan Lee and Chang-Hwan Im
    Citation: Alzheimer's Research & Therapy 2022 14:170
    Content type: Research Published on:

  41. Drug repositioning and repurposing has proved useful in identifying new treatments for many diseases, which can then rapidly be brought into clinical practice. Currently, there are few effective pharmacologica...

    Authors: John T. O’Brien, Leonidas Chouliaras, Janet Sultana, John-Paul Taylor and Clive Ballard
    Citation: Alzheimer's Research & Therapy 2022 14:169
    Content type: Review Published on:

  43. Telomere length (TL) is associated with biological aging, consequently influencing the risk of age-related diseases such as Alzheimer’s disease (AD). We aimed to evaluate the potential causal role of TL in AD ...

    Authors: Blanca Rodríguez-Fernández, Natalia Vilor-Tejedor, Eider M. Arenaza-Urquijo, Gonzalo Sánchez-Benavides, Marc Suárez-Calvet, Grégory Operto, Carolina Minguillón, Karine Fauria, Gwendlyn Kollmorgen, Ivonne Suridjan, Manuel Castro de Moura, David Piñeyro, Manel Esteller, Kaj Blennow, Henrik Zetterberg, Immaculata De Vivo…
    Citation: Alzheimer's Research & Therapy 2022 14:167
    Content type: Research Published on:

  44. Tau-PET is a prognostic marker for cognitive decline in Alzheimer’s disease, and the heterogeneity of tau-PET patterns matches cognitive symptom heterogeneity. Thus, tau-PET may allow precision-medicine predic...

    Authors: Davina Biel, Ying Luan, Matthias Brendel, Paul Hager, Anna Dewenter, Alexis Moscoso, Diana Otero Svaldi, Ixavier A. Higgins, Michael Pontecorvo, Sebastian Römer, Anna Steward, Anna Rubinski, Lukai Zheng, Michael Schöll, Sergey Shcherbinin, Michael Ewers…
    Citation: Alzheimer's Research & Therapy 2022 14:166
    Content type: Research Published on:

  45. Blood adiponectin and leptin are adipokines that emerged as potential biomarkers for predicting Alzheimer’s disease (AD) owing to their strong connection with obesity. Although obesity affects the relation bet...

    Authors: Keun You Kim, Junghee Ha, Minae Kim, So Yeon Cho, Hyunjeong Kim and Eosu Kim
    Citation: Alzheimer's Research & Therapy 2022 14:165
    Content type: Research Published on:

  46. Delaying the transition from minimal cognitive impairment to Alzheimer’s dementia is a major concern in Alzheimer’s disease (AD) therapeutics.

    Authors: José Viña, Joaquín Escudero, Miquel Baquero, Mónica Cebrián, Juan Antonio Carbonell-Asíns, José Enrique Muñoz, Encarnación Satorres, Juan Carlos Meléndez, José Ferrer-Rebolleda, Mª del Puig Cózar-Santiago, Jose Manuel Santabárbara-Gómez, Mariona Jové, Reinald Pamplona, Francisco José Tarazona-Santabalbina and Consuelo Borrás
    Citation: Alzheimer's Research & Therapy 2022 14:164
    Content type: Research Published on:

  47. Obstructive sleep apnoea (OSA) is the most frequent form of sleep-disordered breathing in patients with Alzheimer’s disease (AD). Available evidence demonstrates that both conditions are independently associat...

    Authors: Farida Dakterzada, Iván D. Benítez, Adriano Targa, Anna Carnes, Montse Pujol, Mariona Jové, Olga Mínguez, Rafi Vaca, Manuel Sánchez-de-la-Torre, Ferran Barbé, Reinald Pamplona and Gerard Piñol-Ripoll
    Citation: Alzheimer's Research & Therapy 2022 14:163
    Content type: Research Published on:

  48. Subjective cognitive decline (SCD) is a target for Alzheimer’s disease prediction. Plasma amyloid-beta oligomer (AβO), the pathogenic form of Aβ in blood, has recently been proposed as a novel blood-based biom...

    Authors: Keun You Kim, Jaesub Park, Yong Hyu Jeong, Hyun Jeong Kim, Eun Lee, Jin Young Park, Eosu Kim and Woo Jung Kim
    Citation: Alzheimer's Research & Therapy 2022 14:162
    Content type: Research Published on:

  49. The purpose of this study was to examine the levels of cerebrospinal fluid (CSF) apolipoprotein E (apoE) species in Alzheimer’s disease (AD) patients.

    Authors: Matthew Paul Lennol, Irene Sánchez-Domínguez, Inmaculada Cuchillo-Ibañez, Elena Camporesi, Gunnar Brinkmalm, Daniel Alcolea, Juan Fortea, Alberto Lleó, Guadalupe Soria, Fernando Aguado, Henrik Zetterberg, Kaj Blennow and Javier Sáez-Valero
    Citation: Alzheimer's Research & Therapy 2022 14:161
    Content type: Research Published on:

  50. Studies have reported higher plasma matrix metalloproteinase-9 (MMP-9) levels in mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Despite evidence that MMP-9 activity and its influence on AD patho...

    Authors: Amaryllis A. Tsiknia, Erin E. Sundermann, Emilie T. Reas, Steven D. Edland, James B. Brewer, Douglas Galasko and Sarah J. Banks
    Citation: Alzheimer's Research & Therapy 2022 14:160
    Content type: Research Published on:
Submit manuscript

Follow

  • ISSN: 1758-9193 (electronic)

Alzheimer's Research & Therapy

ISSN: 1758-9193